Clinical trial · Observational
Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses
Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses
NCT01703026CI-TRIAL-00008246completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Consecutive patients over a 1-year period referred for EUS examination due to suspected pancreatic lesions will be enrolled. * Age 21 years and above. * Ability to provide informed consent Exclusion Criteria: Patients with clinical conditions that preclude the use of DEFINITY™ will be excluded. These conditions are: * Right-to-left, bi-directional, or transient right-to-left cardiac shunts; * Worsening or clinically unstable congestive heart failure; * Acute myocardial infarction or acute coronary syndromes; * Serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of the QT interval; * Respiratory failure; * Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature; * Hypersensitivity to DEFINITY™ or its components.
References
Publications (3)
- BACKGROUNDBilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15;110(4):738-44. doi: 10.1002/cncr.22852. PMID 17580363
- BACKGROUNDAng TL. Endoscopic ultrasound: moving from diagnostics to therapeutics. J Dig Dis. 2008 Aug;9(3):117-28. doi: 10.1111/j.1751-2980.2008.00333.x. PMID 18956589
- BACKGROUNDSnady H, Cooperman A, Siegel J. Endoscopic ultrasonography compared with computed tomography with ERCP in patients with obstructive jaundice or small peri-pancreatic mass. Gastrointest Endosc. 1992 Jan-Feb;38(1):27-34. doi: 10.1016/s0016-5107(92)70326-5. PMID 1612375